Outlook Therapeutics (OTLK) Interest Coverage Ratio Growth (1y) (2016 - 2026)
Outlook Therapeutics (OTLK) Interest Coverage Ratio Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -60.78% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -25.59% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1,170.12% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 751.68% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 99.48% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -53.46% |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.86% |
| Dec 31, 2025 | 96.49% |
| Sep 30, 2025 | -100.11% |
| Jun 30, 2025 | -512.66% |
| Mar 31, 2025 | -663.83% |
| Dec 31, 2024 | -670.21% |
| Sep 30, 2024 | 1,603,363.92% |
| Jun 30, 2024 | -77.80% |
| Mar 31, 2024 | -1,890.13% |
| Dec 31, 2023 | -343.41% |
| Sep 30, 2023 | 9,047.40% |
| Jun 30, 2023 | -180.93% |
| Mar 31, 2023 | -12.76% |
| Dec 31, 2022 | 80.18% |
| Sep 30, 2022 | 99.99% |
| Jun 30, 2022 | 99.88% |
| Mar 31, 2022 | 96.48% |
| Dec 31, 2021 | 57.08% |
| Sep 30, 2021 | -1,159.83% |
| Jun 30, 2021 | -18,703.42% |